clinical trial · NCT07158411
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Deciphera Pharmaceuticals, LLC·phase1·completed·n = 22
Healthy ParticipantsVimseltinibMetformin
brief summary
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
started
Nov 20, 2025
primary completion
Jan 30, 2026
completion
Jan 30, 2026
last updated
Feb 11, 2026
official title
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Inhibition in Healthy Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol